AstraZeneca, BenevolentAI Identify New Treatment Target

AstraZeneca, BenevolentAI Identify New Treatment Target

314504

AstraZeneca, BenevolentAI Identify New Treatment Target

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific officer of BenevolentAI, said in a press release. The collaboration between the two companies “uses advanced AI [artificial intelligence] to enable expert scientists to navigate this challenging…

You must be logged in to read/download the full post.